Status:
UNKNOWN
Short Structured Psychological Intervention for Adults With ADHD - a Randomized Controlled Trial
Lead Sponsor:
Cereb AB
Collaborating Sponsors:
Karolinska Institutet
Conditions:
Attention Deficit Disorder With Hyperactivity
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
The purpose of this study is to evaluate the effects of a novel psychological intervention for adult ADHD through a randomized controlled trial. Participants will be randomized to receive either a fac...
Detailed Description
ADHD is associated with deficiencies in short-term memory and executive function, negatively affecting patients' abilities to organize, schedule, multitask, follow through on instructions and finish j...
Eligibility Criteria
Inclusion
- Swedish citizen
- Clinical Diagnosis of ADHD according to DSM-IV or DSM-5.
- Score of 17 or higher on the Adult ADHD Self Report Scale (ASRS v1.1), on any one of the two subscales.
- Not medically treated for ADHD symptoms throughout the study period, or medically treated with central stimulants or comparable substances since at least one month, with no significant changes in dosage and no anticipated significant changes in dosage.
- No change in any other medical treatment for psychiatric symptoms.
- Ability to participate in treatment during the study period.
- Abstinence from illegal substance use for at least three months.
- Access to and ability to use Internet and mobile phone during the study period.
- Ability to understand Swedish in speech and writing, and ability to fill-out forms online.
Exclusion
- Clinical diagnosis of substance use disorder within three months prior to screening. Earlier episodic use of illegal substances is not excluding.
- Co-existing psychiatric condition or disorder expected to render the participant unable to follow-through the study processes.
- IQ ≤85 according to a prior neuropsychological assessment.
- Suicidality assessed at the first assessment interview.
- Organic brain syndrome.
- Autism spectrum disorder (ASD) where function is deemed too low for the treatment to be carried out, defined as ASD level 2 and level 3 according to DSM-5 and/or ASD with accompanying intellectual impairment and/or accompanying language impairment.
- Severe depression, defined as \>34 on the MADRS-S or at a clinical assessment.
- Other current psychological treatment for ADHD or prior participation in treatment deemed to interfere with the study design.
- Limited or very limited self-rated recognition of problems regarding impulse control and/or emotional instability, in combination with low self-rated impairment, on a tailor-made measure.
Key Trial Info
Start Date :
August 25 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2022
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04439422
Start Date
August 25 2020
End Date
August 1 2022
Last Update
October 14 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cereb AB
Stockholm, Sweden